Practices must prepare for stricter fraud reporting and compliance as the DOJ Corporate Whistleblower Awards Pilot Program and bipartisan AI Whistleblower Protection Act expand protections beyond the False Claims Act.
© Victor Moussa - stock.adobe.com
When most people think of a whistleblower bringing information regarding fraud to the government in exchange for a portion of the recovery, as well as related whistleblower protections, the False Claims Act, 31 U.S.C. §§3729-3733 (FCA), usually comes to mind. Rightly so, the FCA was passed by Congress and signed into law in 1863. Its primary purpose is to enable private citizens, through its qui tam provision, to assist in the return of ill-gotten payments to the Federal Fisc (and in some cases, respective States, too).
On August 1, 2024, the U.S. Department of Justice (DOJ) announced the Corporate Whistleblower Awards Pilot Program (DOJ Pilot Program). While there is the word “whistleblower” in the title and an individual can bring forth good faith allegations of fraud for a portion of a recovery, it has numerous distinctions from the FCA. On May 12, the DOJ revised its guidance regarding the DOJ Pilot Program. Here are some of the key items to appreciate:
These are just a few of the nuances of this program.
Announced by Senator Grassley on May 15, the Artificial Intelligence (AI) Whistleblower Protection Act, which is bi-partisan legislation “merges existing AI and whistleblower protection laws to shield the communications of current and former AI employees who make disclosures.” The legislation sets forth two (2) types of AI violations – violation of any Federal law related to or committed during the development, deployment, or use of AI; or any failure to respond to a specific threat. Notably, this whistleblower protection should be read in par materia with the FCA, SEC and DOJ Pilot Program among others.
For the health care sector, these two items underscore the importance of a comprehensive compliance program, anti-retaliation provisions for good faith concerns and appreciating that AI can lead to a false and fraudulent claim.
Rachel V. Rose, JD, MBA, advises clients on compliance, transactions, government administrative actions, and litigation involving healthcare, cybersecurity, corporate and securities law, as well as False Claims Act and Dodd-Frank whistleblower cases. She also teaches bioethics at Baylor College of Medicine in Houston. Rachel can be reached through her website, www.rvrose.com.